[National Medical Insurance Administration: More innovative drugs are expected to be included in medical insurance reimbursement] On September 4, Li Tao, deputy director of the National Medical Insurance Administration, said at the "Starting the 15th Five-Year Plan" series of themed press conferences held by the State Council Information Office on September 4 that the basic medical insurance drug catalog will continue to be adjusted every year to include more qualified innovative drugs in major diseases such as tumors, chronic diseases, rare diseases, and childhood diseases, and in key areas, into medical insurance reimbursement, and efforts will be made to promote the national unification of medical service items and medical consumables reimbursement catalogs to further narrow policy differences between regions.